An open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2 targeted therapy related cardiac dysfunction.

30 August 2026 (11:15 - 11:30)
Organised by: Logo
Congress Presentation Part of: Late-Breaking Clinical Science: cardio-oncology Cardio-Oncology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology